Drug Profile

MORF 720

Alternative Names: MORF-720

Latest Information Update: 22 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Harvard Medical School; Morphic Therapeutic
Developer Eli Lilly and Company
Class Antifibrotics; Small molecules
Mechanism of Action Integrin alphaVbeta6 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

16 Aug 2024 Morphic Therapeutic has been acquired and merged into Eli Lilly and Company
24 Feb 2022 AbbVie discontinues the development activities for aVß6 target
23 Feb 2022 Discontinued - Preclinical for Idiopathic pulmonary fibrosis in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com